医学
特发性肺纤维化
间质性肺病
内科学
安慰剂
临床终点
中止
肺活量
胃肠病学
临床研究阶段
临床试验
肺
病理
扩散能力
替代医学
肺功能
作者
Tamera J. Corte,Lisa Lancaster,Jeffrey J. Swigris,Toby M. Maher,Jonathan G. Goldin,Scott M. Palmer,Takafumi Suda,Takashi Ogura,A. Minnich,Xiaojiang Zhan,Giridhar S. Tirucherai,Brandon Elpers,Hong Xiao,Hideaki Watanabe,Ralph Adam Smith,Edgar D. Charles,Aryeh Fischer
标识
DOI:10.1136/bmjresp-2021-001026
摘要
Idiopathic pulmonary fibrosis (IPF) and non-IPF, progressive fibrotic interstitial lung diseases (PF-ILD), are associated with a progressive loss of lung function and a poor prognosis. Treatment with antifibrotic agents can slow, but not halt, disease progression, and treatment discontinuation because of adverse events is common. Fibrotic diseases such as these can be mediated by lysophosphatidic acid (LPA), which signals via six LPA receptors (LPA1-6). Signalling via LPA1 appears to be fundamental in the pathogenesis of fibrotic diseases. BMS-986278, a second-generation LPA1 antagonist, is currently in phase 2 development as a therapy for IPF and PF-ILD.This phase 2, randomised, double-blind, placebo-controlled, parallel-group, international trial will include adults with IPF or PF-ILD. The trial will consist of a 42-day screening period, a 26-week placebo-controlled treatment period, an optional 26-week active-treatment extension period, and a 28-day post-treatment follow-up. Patients in both the IPF (n=240) and PF-ILD (n=120) cohorts will be randomised 1:1:1 to receive 30 mg or 60 mg BMS-986278, or placebo, administered orally two times per day for 26 weeks in the placebo-controlled treatment period. The primary endpoint is rate of change in per cent predicted forced vital capacity from baseline to week 26 in the IPF cohort.This study will be conducted in accordance with Good Clinical Practice guidelines, Declaration of Helsinki principles, and local ethical and legal requirements. Results will be reported in a peer-reviewed publication.NCT04308681.
科研通智能强力驱动
Strongly Powered by AbleSci AI